| propafenone vs flecainide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 1.06 [0.58 1.94] | p=1.00 | 0 | 200 | 1 | FAPIS, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 2.12 [0.19 23.80] | p=1.00 | 0 | 200 | 1 | FAPIS, | | All cause death | 1.06 [0.02 54.05] | p=1.00 | 0 | 200 | 1 | FAPIS, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 1.18 [0.46 3.04] | p=1.00 | 0 | 200 | 1 | FAPIS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| propafenone vs placebo | No demonstrated result suggested Atrial fibrillation recurrence by 33% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.67 [0.50 0.89] | p=0.04 | 0 | 1098 | 5 | Bellandi (propafenone vs placebo),Dogan,Kochiadakis b (propafenone vs placebo),RAFT,Stroobandt, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 0.96 [0.27 3.39] | p=1.00 | 0 | 1098 | 5 | Bellandi (propafenone vs placebo),Dogan,Kochiadakis b (propafenone vs placebo),RAFT,Stroobandt, | | All cause death | 0.34 [0.07 1.72] | p=1.00 | 0 | 1098 | 5 | Bellandi (propafenone vs placebo),Dogan,Kochiadakis b (propafenone vs placebo),RAFT,Stroobandt, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 1.56 [0.96 2.53] | p=1.00 | 0 | 1098 | 5 | Bellandi (propafenone vs placebo),Dogan,Kochiadakis b (propafenone vs placebo),RAFT,Stroobandt, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| propafenone vs quinidine | No demonstrated result suggested Adverse events leading to treatment discontinuation by 139% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 1.12 [0.64 1.96] | p=1.00 | 0 | 200 | 1 | Richiardi, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 1.04 [0.14 7.54] | p=1.00 | 0 | 200 | 1 | Richiardi, | | All cause death | 0.21 [0.01 4.39] | p=1.00 | 0 | 200 | 1 | Richiardi, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 2.39 [1.07 5.34] | p=0.04 | 0 | 200 | 1 | Richiardi, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| propafenone vs sotalol | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.91 [0.40 2.11] | p=1.00 | 0 | 100 | 1 | Reimold, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 1.50 [0.49 4.58] | p=1.00 | 0 | 100 | 1 | Reimold, | | All cause death | 5.00 [0.23 106.89] | p=1.00 | 0 | 100 | 1 | Reimold, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 1.50 [0.40 5.68] | p=1.00 | 0 | 100 | 1 | Reimold, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
